Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis

NCT05647096 is registered in ClinicalTrials.gov with Santersus AG as lead sponsor.

NCT NCT05647096
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05647096 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating CfDNA/NETs in Subjects with Sepsis
Lead sponsor
Santersus AG
Phase
Not applicable
Overall status
Not yet recruiting
Start date
July 1, 2025
Completion date
May 28, 2027
Enrollment
73 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

respiratory failure, sepsis